- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00384969
Sorafenib and RAD001 Renal Cell Carcinoma
A Phase I Study of Sorafenib and RAD001 in Patients With Metastatic Renal Cell Carcinoma
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
California
-
San Francisco, California, Förenta staterna, 94115
- University of California, San Francisco
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Histologically- or cytologically-confirmed renal cell carcinoma containing predominant (>50%) clear cell histology, which is metastatic or unresectable
- Cytoreductive nephrectomy is allowed
- Evidence of RECIST-defined measurable disease (lesions that can be accurately measured in at least one dimension with the longest diameter ≥ 20mm using conventional techniques or ≥10 mm with spiral CT scan)
- Male or female at least 21 years old
- ECOG performance status 0-1
Adequate bone marrow function:
- ANC ≥ 1500/uL
- platelet count ≥ 100,000/uL
- hemoglobin ≥ 9.0 g/dL
Adequate hepatic function:
- Total bilirubin ≤ 1.5 X ULN
- AST (SGOT) ≤ 2.5 X ULN
- ALT (SGPT) ≤ 2.5 X ULN
Adequate renal function as determined by either:
Calculated or measured creatinine clearance ≥ 40 mL/min (for calculated creatinine clearance, Cockroft-Gault equation will be used) Modified Cockcroft-Gault formula: ((140 - age(yrs)) x (actual weight(kg))) / (72 x serum creatinine(mg/dl))
* Multiply by another factor of 0.85 if female
- Serum creatinine ≤ 1.5 X ULN
- Able to swallow oral medications
- Resolution of any pre-existing toxicity from prior therapy to NCI CTCAE V3.0 ≤ grade 1
- Signed and dated informed consent document
- Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
- More than 28 days since any prior therapy, including investigational agents and surgical procedures
Exclusion Criteria:
- Collecting duct, papillary, or chromophobe type renal cell carcinoma without a clear cell component are excluded. Transitional cell carcinoma of the renal pelvis is excluded
- No more than two prior systemic regimens for renal cell carcinoma
- Phase I: No prior treatment with sorafenib. Phase II: No prior treatment with prior anti-VEGF therapies, including sorafenib, sunitinib, thalidomide, or bevacizumab
- No prior treatment with RAD001, CCI-779, or similar agents
- Prior surgery, radiation therapy, or systemic therapy for renal cell carcinoma within 4 weeks of starting study treatment
- History of or known brain metastasis, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease on screening CT or MRI scan
- Any of the following within 12 months prior to study drug administration: myocardial infarction, unstable or severe angina, coronary or peripheral artery bypass graft, NYHA functional Class II, III, IV congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism
- Hypertension that is unable to be controlled with medications
- Known human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS)-related illness
- "Currently active" second malignancy other than non-melanoma skin cancers. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are considered to have a less than 30% risk of relapse
- Current treatment on another clinical trial
- Pregnant or breastfeeding
- Chronic treatment with systemic steroids or other immunosuppressive agent
- Patients with an active bleeding diathesis or on oral vitamin K antagonist medication (except low dose warfarin)
- History of malabsorption syndrome, disease significantly affecting gastrointestinal function or major resection of stomach or small bowel that could interfere with absorption, distribution, metabolism, or excretion of study drugs
- Any serious and/or unstable pre-existing medical, psychiatric, or other condition (including lab abnormalities) that could interfere with subject safety or obtaining informed consent. Examples of such include uncontrolled diabetes, nonhealing wound, severe infection, severe malnutrition, ventricular arrhythmias, active ischemic heart disease, chronic liver or renal disease, or active upper GI tract ulceration -
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: 1
RAD001 and Sorafenib
|
RAD001 2.5mg to 10.0mg PO QD Sorafenib 400mg PO BID
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Maximal tolererad dos
Tidsram: varje vecka
|
varje vecka
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Objektiv svarsfrekvens
Tidsram: 8 veckor
|
8 veckor
|
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Huvudutredare: Charles Ryan, MD, University of California, San Francisco
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Neoplasmer efter histologisk typ
- Neoplasmer
- Urologiska neoplasmer
- Urogenitala neoplasmer
- Neoplasmer efter plats
- Njursjukdomar
- Urologiska sjukdomar
- Adenocarcinom
- Neoplasmer, körtel och epitel
- Neoplasmer i njurarna
- Karcinom, njurcell
- Carcinom
- Läkemedels fysiologiska effekter
- Molekylära mekanismer för farmakologisk verkan
- Enzyminhibitorer
- Antineoplastiska medel
- Immunsuppressiva medel
- Immunologiska faktorer
- Proteinkinashämmare
- Sorafenib
- Everolimus
Andra studie-ID-nummer
- UCSF06523
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Njurcellscancer
-
Mabwell (Shanghai) Bioscience Co., Ltd.Har inte rekryterat ännuAvancerat clear cell renal cell carcinom
-
AmgenAvslutadNjurcellscancer | Clear Cell Renal Cell Carcinom | Clear Cell Renal Carcinom | NjurcellsadenokarcinomFrankrike, Förenta staterna, Tyskland
-
Norroy Bioscience Co., LTDRekryteringClear Cell Renal Cell Carcinom MetastaserandeKina
-
Bradley A. McGregor, MDPfizerIndragenAvancerat clear cell renal cell carcinomFörenta staterna
-
Yousef ZakhariaUniversity of IowaRekryteringClear Cell Renal Cell Carcinom | Clear Cell Renal Cell Carcinom MetastaserandeFörenta staterna
-
Telix International Pty LtdGrand Pharmaceutical (China) Co., Ltd.AvslutadClear Cell Renal Cell Carcinom | Återkommande njurcellscancer | Misstänkt återkommande renal clear cell carcinomKina
-
ExelixisArcus Biosciences, Inc.RekryteringAdvanced Clear Cell Renal Cell Carcinom eller andra avancerade solida tumörerFörenta staterna
-
Yonsei UniversityRekryteringNjurcancer | Synkron neoplasma | Clear Cell Renal Cell Carcinom MetastaserandeKorea, Republiken av
-
Peloton Therapeutics, Inc.Aktiv, inte rekryterandeNjurcancer | Njurcellscancer | Njurcancer | Njurcellscancer (RCC) | Njurcellscancer Metastaserande | Njure | Clear Cell Renal Cell Carcinom (ccRCC) | Njurcellscancer återkommande | Njurcellscancer, återkommandeFörenta staterna
-
RenJi HospitalShanghai Zhongshan Hospital; Ruijin HospitalRekryteringClear Cell Renal Cell Carcinoma、Resistens mot immunterapiKina
Kliniska prövningar på RAD001 and Sorafenib
-
Southern Europe New Drug OrganizationBayer; NovartisUpphängdAvancerade solida tumörerItalien
-
Novartis PharmaceuticalsAvslutadHepatocellulärt karcinomFörenta staterna, Spanien, Korea, Republiken av, Nederländerna, Taiwan
-
University of CologneAvslutadIcke-småcellig lungcancer | Ospecificerad fast tumör för vuxen, protokollspecifikTyskland
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI); NovartisAktiv, inte rekryterandeRefraktär Hurthle-cellsköldkörtelcancerFörenta staterna
-
Dana-Farber Cancer InstituteBayer; NovartisAvslutadNeuroendokrin tumör | Karcinoid tumör | Pankreas neuroendokrina tumörerFörenta staterna
-
Mayo ClinicUniversity of IowaAvslutadLymfom | Multipelt myelom och plasmacellsneoplasmaFörenta staterna
-
The Methodist Hospital Research InstituteNovartis PharmaceuticalsAvslutadKarcinom, njurcellFörenta staterna
-
SCRI Development Innovations, LLCBayer; NovartisAvslutadNjurcancerFörenta staterna
-
University Hospitals Cleveland Medical CenterOkändAstma | Allergisk rinit | Allergisk konjunktivitFörenta staterna
-
University of PittsburghCitrone 33 FoundationAvslutad